放射性药物市场规模、份额、成长分析，按类型、按适应症、按系统、按应用、按最终用户、按地区 - 行业预测 2024-2031

2022年全球放射性药物市场规模为65.2亿美元，从2023年的67.4亿美元成长到2031年的88.1亿美元，预测期间（2024-2031年）预计复合年增长率为3.4%。

PET（正子断层扫描）和 SPECT（单光子发射电脑断层扫描）等诊断影像技术的进步彻底改变了医疗保健领域。这些创新显着提高了诊断慢性疾病的特异性和敏感性，从而实现更快、更准确的诊断。一个值得注意的例子是，2023 年 6 月，GE Healthcare 推出了首款临床实验PET 核子医学影像产品，旨在检测和预测癌症免疫疗法的反应。癌症、阿兹海默症和心臟病等慢性疾病的盛行率不断上升，支持了对这些先进诊断工具不断增长的需求。美国癌症协会预测，到2024年，美国将新增约299,000例前列腺癌病例，每年有八分之一的男性被诊断出来。此外，根据阿兹海默症协会的资料，目前约有 690 万 65 岁以上的美国人患有阿兹海默症，预计到 2060 年这一数字将增加至 1,380 万。慢性病的快速成长不仅凸显了诊断影像技术在诊断和治疗中的重要作用，也为医疗保健产业的相关人员带来了巨大的市场成长机会。随着对精确诊断解决方案的需求持续成长，投资创新成像技术可能会在不断发展的医疗保健市场中产生丰厚的回报。

目录

介绍

• 研究目的
• 定义
• 市场范围

调查方法

• 资讯采购
• 二手资料来源和主要资料来源
• 市场规模预测
• 市场假设与限制

执行摘要

• 市场概况展望
• 供需趋势分析
• 按细分市场的机会分析

市场动态及展望

• 市场动态
  • 促进因素
  • 机会
  • 抑制因素
  • 任务
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 专利分析
• 监管环境
• 技术景观
• PESTEL分析
• 价值链分析
• 供应链分析

放射性药物市场：依类型

• 市场概况
• 氟18衍生物
  • 氟18氟脱氧葡萄糖（FDG）
  • 氟18氟化钠
  • 氟18氟昔考宾
  • 氟-18氟倍他吡
  • 氟-18氟苯甲酸酯
  • 其他的
• Technetium99
• 镏(Lu) 177
• 镓68
  • DOTATATE
  • DOTATOC
• 锆89
  • 11C-胆碱
  • 14C-尿素
• 其他的

放射性药物市场：依适应症分类

• 市场概况
• 诊断
  • 神经病学
  • 神经退化性疾病（AD、PD 等）
  • 癫痫
• 心臟病学
• 其他的

放射性药物市场：依系统分类

• 市场概况
• PET
  • 独立 PET 系统
  • 混合PET/CT
  • 混合PET/MRI
• SPECT

放射性药物市场：依应用分类

• 市场概况
• 肿瘤学
• 心臟病学
• 胃肠病学
• 神经内分泌学
• 神经病学
• 肾臟病学
• 其他的

放射性药物市场：依最终用户分类

• 市场概况
• 医院
• 诊断实验室
• 其他的

放射性药物市场：按地区

• 市场概况
• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲 (MEA)
  • 海湾合作委员会国家
  • 南非
  • 其他中东/非洲地区

竞争格局

• 前5名企业对比
• 主要企业市场定位（2023年）
• 主要市场参与者所采取的策略
• 近期市集活动
• 主要企业市场占有率（2023年）

主要企业简介

• Cardinal Health（US）
• Novartis Company（Switzerland）
• Lantheus（US）
• Curium（France）
• GE HealthCare（US）
• Jubilant Pharma Company（India）
• China Isotope & Radiation Corporation（China）
• Siemens Healthcare GmbH（Germany）
• Bracco（Italy）
• NTP（South Africa）
• Eckert & Ziegler（Germany）
• SHINE Technologies, LLC（US）
• EczacIbasI-Monrol（Turkey）
• IBA Worldwide（Belgium）
• Global Medical Solutions（US）
• BWX Technologies, Inc.（US）
• Institute of Isotopes（Hungary）
• Coqui Radiopharmaceuticals Corp.（US）
• Evergreen Theragnostics, Inc.（US）
• Isotope JSC（Russia）
• PharmaLogic Holdings Corp.（US）

Global Radiopharmaceuticals Market size was valued at USD 6.52 billion in 2022 and is poised to grow from USD 6.74 billion in 2023 to USD 8.81 billion by 2031, growing at a CAGR of 3.4% in the forecast period (2024-2031).

The healthcare landscape has been transformed by advances in imaging techniques like PET (Positron Emission Tomography) and SPECT (Single Photon Emission Computed Tomography), which leverage radiopharmaceuticals to enhance the diagnostic capabilities of traditional imaging modalities, including CT and MRI. These innovations have significantly improved specificity and sensitivity in diagnosing chronic diseases, facilitating earlier and more accurate characterizations. A notable example is GE Healthcare's launch in June 2023 of the first investigational PET nuclear imaging product designed to detect and predict responses to cancer immunotherapies. The rising prevalence of chronic conditions such as cancer, Alzheimer's disease, and heart disease underscores the growing need for these advanced diagnostic tools. Projections from the American Cancer Society indicate that by 2024, there will be approximately 299,000 new prostate cancer cases in the U.S., with 1 in 8 men diagnosed annually. Moreover, data from the Alzheimer's Association reveals that approximately 6.9 million Americans aged 65 and older currently suffer from Alzheimer's disease, a figure expected to escalate to 13.8 million by 2060. This surge in chronic conditions not only highlights the critical role of enhanced imaging techniques in diagnosis and treatment but also signals significant market growth opportunities for stakeholders within the healthcare sector. As demand for precise diagnostic solutions continues to rise, investing in innovative imaging technologies is likely to yield substantial returns in the evolving healthcare market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Radiopharmaceuticals market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Radiopharmaceuticals Market Segmental Analysis

Global Radiopharmaceuticals Market is segmented on the type, indication, system, application, end user, and region. By component, market is segmented into fluorine-18 derivatives, technetium-99, lutetium (Lu) 177, gallium-68, zirconium-89, and others. By indication, market is segmented into diagnosis, cardiology, and others. By system, market is segmented into PET, and SPECT. By Application, the market is segmented into Oncology, Cardiology, Gastroenterology, Neuroendocrinology, Neurology, Nephrology, Others. By end user, market is segmented into Hospitals, Diagnostic Labs, and Others. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Driver of the Global Radiopharmaceuticals Market

The escalating incidence of cancer globally is a significant market driver for the Global Radiopharmaceuticals market, as these specialized compounds play a crucial role in targeted and diagnostic oncology. With their ability to provide precise tumor localization and deliver therapeutic agents directly to malignant tissues, radiopharmaceuticals enhance treatment efficacy while minimizing adverse effects. This targeted approach not only improves patient outcomes but also aligns with the rising demand for personalized medicine, further fueling market growth. As healthcare systems increasingly prioritize advanced cancer therapies, the reliance on radiopharmaceuticals is expected to surge, propelling sustained investment and innovation in this sector.

Restraints in the Global Radiopharmaceuticals Market

The stringent regulatory framework governing the manufacture and approval of radiopharmaceuticals serves as a significant market restraint, hindering the growth potential of the sector. Compliance with rigorous safety and quality standards necessitates substantial investments in research, development, and manufacturing processes, often resulting in delayed product launches. The lengthy approval processes imposed by regulatory bodies further exacerbate these challenges, restricting market access for new therapeutic agents and imaging compounds. As manufacturers navigate the complexities of regulatory requirements, the resulting operational hurdles can deter investment and innovation, placing limitations on the overall expansion of the global radiopharmaceuticals market.

Market Trends of the Global Radiopharmaceuticals Market

The Global Radiopharmaceuticals market is witnessing a robust trend towards personalized medicine, driven by the increasing demand for targeted therapies that cater to individual patient profiles. This shift is particularly prominent in oncology and cardiology, where the ability to customize treatments based on specific genetic and disease characteristics enhances the efficacy of radiopharmaceuticals. As healthcare providers emphasize precision medicine, investments in research and development for innovative radiopharmaceuticals are on the rise. Consequently, this trend not only improves patient outcomes but also propels market growth, as stakeholders seek to harness the full potential of targeted therapies in clinical practice.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factor
• Degree of Competition
• Top Investment Pockets
• Ecosystem of the Market
• Patent Analysis
• Regulatory Landscape
• Technological Landscape
• PESTEL Analysis
• Value Chain Analysis
• Supply Chain Analysis

Radiopharmaceuticals Market, By Type

• Market Overview
• Fluorine-18 Derivatives
  • Fluorine-18 Fludeoxyglucose (FDG)
  • Fluorine-18 Sodium Fluoride
  • Fluorine-18 Flucicovine
  • Fluorine-18 Florbetapir
  • Fluorine-18 Florbetaben
  • Others
• Technetium-99
• Lutetium (Lu) 177
• Gallium-68
  • Dotatate
  • Dotatoc
• Zirconium 89
  • 11C-choline
  • 14C-urea
• Others

Radiopharmaceuticals Market, By Indication

• Market Overview
• Diagnosis
  • Neurology
  • Neurodegenerative Disease (AD, PD, and Others)
  • Epilepsy
• Cardiology
• Others

Radiopharmaceuticals Market, By System

• Market Overview
• PET
  • Standalone PET systems
  • Hybrid PET/CT
  • Hybrid PET/MRI
• SPECT

Radiopharmaceuticals Market, By Application

• Market Overview
• Oncology
• Cardiology
• Gastroenterology
• Neuroendocrinology
• Neurology
• Nephrology
• Others

Radiopharmaceuticals Market, By End User

• Market Overview
• Hospitals
• Diagnostic Labs
• Others

Radiopharmaceuticals Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• Cardinal Health (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis Company (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lantheus (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Curium (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GE HealthCare (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jubilant Pharma Company (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• China Isotope & Radiation Corporation (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthcare GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bracco (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NTP (South Africa)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eckert & Ziegler (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SHINE Technologies, LLC (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• EczacIbasI-Monrol (Turkey)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• IBA Worldwide (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Global Medical Solutions (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BWX Technologies, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Institute of Isotopes (Hungary)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Coqui Radiopharmaceuticals Corp. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Evergreen Theragnostics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Isotope JSC (Russia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PharmaLogic Holdings Corp. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments